Sodium Sulfacetamide NDC 44523-613

NDC codes

FDA NDC Directory

Product NDC (as listed)44523-613Labeler and product segments. Claims need a package NDC.

Product NDC at billing width44523-0613Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
44523-613-06	44523061306	177 mL in 1 BOTTLE, PLASTIC (44523-613-06)Marketed from Sep 7, 2011

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Sodium Sulfacetamide
Generic name (nonproprietary): sodium sulfacetamide
Active ingredients: Sulfacetamide sodium — 100 mg/mL
Dosage form: Liquid
Route: Topical
Labeler: BioComp Pharma, Inc.
Product type: Prescription drug
Marketing category: Unapproved drug (other)
Marketing start: Sep 7, 2011
Listing expires: Dec 31, 2027
Other FDA classes: Sulfonamides (Chemical structure)
Identifiers: Product ID 44523-613_4839e157-d35d-c2f2-e063-6394a90ae389SPL ID 4839e157-d35d-c2f2-e063-6394a90ae389SPL set ID efde52a6-216d-4ccc-8574-5e3e41ec7e06RxCUI 1006107UNII 4NRT660KJQ
Pharmacologic class: Sulfonamide Antibacterial

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Topical products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N444523061306 followed by a unit qualifier and the quantity

Package 44523-0613-06. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 12, 2026.

Indications (excerpt from the label)

INDICATIONS: This product is intended for topical application in the following scaling dermatoses: seborrheic dermatitis and seborrhea sicca (dandruff). It also is indicated for the treatment of secondary bacterial infections of the skin due to organisms susceptible to sulfonamides.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)